
Roche and Nurix Enter $2.3 Billion Deal to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have entered a collaboration valued at up to $2.3 billion to jointly develop and commercialize bexobrutideg (NX-5948), Nurix’s investigational BTK degrader.








